Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care

Annals of the Rheumatic Diseases

Volumn 64, Issue 5, 2005, Pages 659-663

  Sieper, J ^a,b   Rudwaleit, M ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ANKYLOSING SPONDYLITIS; BACKACHE; CLINICAL EXAMINATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; INFLAMMATORY DISEASE; LABORATORY DIAGNOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT REFERRAL; PHYSIOTHERAPY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SCREENING; SERODIAGNOSIS; SIDE EFFECT; SPINE RADIOGRAPHY; TREATMENT PLANNING;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BACK PAIN; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; HLA-B27 ANTIGEN; HUMANS; MASS SCREENING; PRIMARY HEALTH CARE; REFERRAL AND CONSULTATION; SPONDYLITIS, ANKYLOSING;

EID: 17644399153     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.028753     Document Type: Review

References (33)

1. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003;23:61-6.
2. van der Linden S, van der Heijde D. Ankylosing spondylitis. Clinical features [review]. Rheum Dis Clin North Am 1998;24:663-76, vii.
3. van der Linden S, Valkenburg H, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals: a family and population study. Br J Rheumatol 1983;22(suppl 2):18-19.
4. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
5. Gran JT, Husby G, Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population or Tromso, northern Norway. Ann Rheum Dis 1985;44:359-67.
6. Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden S, Brandt J. Conventional treatments for ankylosing spondylitis [review]. Ann Rheum Dis 2002;61(suppl III):iii40-50.
7. Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open lable trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 2005;64:124-6.
8. van der Heijde DMF, Wanders A, Spoorenberg A, van der Linden S, Dougados M, van der Tempel H, et al. Structural damage assessed on radiographs in patients with anklyosing spondylitis steadily increases over time [abstract]. Arthritis Rheum 2003;48(suppl):S175.
9. Amor B, Dougados M, Listrat V, Menkes CJ, Roux H, Benhamou C, et al. Are classification criteria for spondylarthropothy useful as diagnostic criteria? Rev Rhum Engl Ed 1995;62:10-15.
10. Dougados M, Behier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001;44:180-5.
11. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
12. van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002;46:755-65.
13. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
14. Dovis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
15. Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36.
16. Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C. Increase in bone mineral density of patients with spondyloarthropathy treated with antitumour necrosis factor α. Ann Rheum Dis 2003;62:347-9.
17. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor a blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70.
18. Underwood MR, Dawes P. Inflammatory back pain in primary care. Br J Rheumatol 1995;34:1074-7.
19. Deyo RA, Weinstein JN. Low back pain. N Engl J Med 2001;344:363-70.
20. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
21. Mau W, Zeidler H, Mau R, Majewski A, Freyschmidt J, Stangel W, et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumotol 1988;15:1109-14.
22. Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994;37:1039-45.
23. Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004;63:535-43.
24. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
25. Calin A, Porta J, Fries JF, Schurman DJ. Clinical history as a screening test for ankylosing spondylitis. JAMA 1977;237:2613-14.
26. Amor B, Santos RS, Nahal R, Listrat V, Dougados M. Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 1994;21:1883-7.
27. van Tubergen A, Heuft-Dorenbosch L, Schulpen G, Landewé R, Wijers R, van der Heijde D, et al. Radiographic assessment of sacroiliitis by radiologists and rheumatologists: does training improve quality? Ann Rheum Dis 2003;62:519-25.
28. van der Heijde DMFM, Wanders A, Mielants H, Dougados M, Landewè RBM. Prediction of progression of radiographic damage over 4 years in patients with ankylosing spondylitis [abstract]. Ann Rheum Dis 2004;63(suppl 1):98.
29. Gran JT, Nordvag BY. Referrals from general practice to an outpatient rheumatology clinic: disease spectrum and analysis of referral letters. Clin Rheumatol 2000;19:450-4.
30. Khan MA, Khan MK. Diagnostic value of HLA-B27 testing ankylosing spondylitis and Reiter's syndrome. Ann Intern Med 1982;96:70-6.
31. Jajic I. The role of HLA-B27 in the diagnosis of low back pain. Acta Orthop Scand 1979;50:411-13.
32. Sandstrom J, Andersson GB, Rydberg L. HLA-B27 as a diagnostic screening tool in chronic low back pain. Scand J Rehabil Med 1984;16:27-8.
33. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002;61:290-7.